Latest News

 Filter by Provider

Game engine maker Unity (NYSE:U) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.9% year on year to $440.9 million. On the other hand, next quarter’s revenue guidance of $445 million was less impressive, coming in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.18 per share was 22% above analysts’ consensus estimates.

Bioventus Inc. (BVS) reports mixed Q2 2025 results with slight revenue miss but EPS near estimates. Organic growth up 6.2%, yet stock dips 2% pre-market.

Vishay Intertechnology (VSH) missed Q2 2025 earnings and revenue estimates, posting a loss per share. Shares show mixed reaction amid broader declines. Analysts watch for Q3 recovery.

NZD/USD has rebounded to the upper bound of the trading range under the 200-period moving average MA(200) which is declining.

Trimble Inc. (TRMB) reported strong Q2 2025 results, beating revenue and EPS estimates. Stock surged 5.8% pre-market on raised guidance and optimistic outlook.

The New York Times Q2 2025 earnings beat estimates with $685.87M revenue and $0.58 EPS, driving a 5.37% pre-market stock surge. Subscriber growth and bundling strategies fuel optimism.

These stocks are benefiting from improvements in consumer spending.

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Gilat Satellite Networks reports strong Q2 2025 earnings, beating revenue and EPS estimates, raising guidance, and sparking an 8% pre-market stock surge.

Banking and retail technology provider Diebold Nixdorf (NYSE:DBD) announced better-than-expected revenue in Q2 CY2025, but sales fell by 2.6% year on year to $915.2 million. Its GAAP profit of $0.33 per share was 17.5% below analysts’ consensus estimates.

Lexicon Pharmaceuticals (LXRX) reports strong Q2 2025 earnings with $28.9M revenue, beating estimates by 482%. Stock rises 9.5% on profit surprise and pipeline progress.

Vertex Inc. (VERX) Q2 2025 earnings missed revenue estimates at $184.6M but beat EPS at $0.15. Shares fell 5.2% pre-market amid growth concerns.

MannKind Corp (MNKD) missed Q2 2025 revenue and EPS estimates, causing a 3.8% pre-market drop. Despite the miss, strategic moves like Blackstone's $500M financing and product pipeline progress offer long-term optimism.

EHEALTH INC (NASDAQ:EHTH) reported strong Q2 2025 results, with revenue beating estimates by 29.7% and a narrower-than-expected loss. Shares surged 13.76% pre-market.

McDonald's stock looks to rebound above key line on earnings. Comparable sales, customer spending grow.

Gaming company Inspired (NASDAQ:INSE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 6.2% year on year to $80.3 million. Its non-GAAP loss of $0.19 per share was significantly below analysts’ consensus estimates.

Inspired Entertainment's Q2 2025 results show revenue beat but unexpected EPS loss, sparking pre-market stock decline. Interactive segment shines with 45% growth.

Arvinas Q2 2025 earnings: Revenue missed estimates at $22.4M, but EPS beat at -$0.84. NDA submitted for vepdegestrant, ARV-102 advances in trials. Shares fell pre-market.

Entrada Therapeutics (TRDA) missed Q2 2025 revenue and EPS estimates, posting $1.95M revenue vs. $9.84M expected and a $1.04 loss per share. Shares fell 2% pre-market amid investor concerns. Pipeline progress includes DMD trials and regulatory filings.

Seres Therapeutics reports Q2 2025 results with $0.0 revenue and a narrower EPS loss of $2.27, beating estimates. Shares dip 4.5% pre-market despite recent 23% gain. Progress noted in SER-155 clinical trials.

Mirum Pharmaceuticals (MIRM) fits Mark Minervini's trend-following strategy with strong technicals, revenue growth, and breakout potential. A high-growth momentum stock worth watching.

Kornit Digital (KRNT) reported mixed Q2 2025 results, missing revenue estimates at $49.8M but beating EPS with $0.03. Shares dipped slightly as investors weighed the performance.

Ceragon Networks (CRNT) Q2 2025 earnings miss estimates, with revenue at $82.26M and EPS $0.03, triggering a 12.8% pre-market drop. Investors react to weak demand and margin pressures.

McDonald's has reported a significant increase in global comparable sales for Q2 2025, outperforming market expectations.

Chinese automakers and chip companies are racing to replace foreign chips in self-driving tech, after U.S. export restrictions hurt sales and demand.

Meme stocks had a huge week; earnings season got into full swing with Alphabet going big on AI.

The new CEO is refusing to spend more until it has a clear pipeline of revenue.

Cash management services provider Brink's (NYSE:BCO) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.8% year on year to $1.30 billion. Guidance for next quarter’s revenue was better than expected at $1.33 billion at the midpoint, 2% above analysts’ estimates. Its non-GAAP profit of $1.79 per share was 23.7% above analysts’ consensus estimates.

Merck & Co. (MRK) is a top dividend stock with a 4.06% yield, strong profitability, and solid financials, making it a reliable choice for income investors.

Platinum, best-performing commodity in 2025, faces sustained demand outstripping supply. Record imports, soaring lease rates, and shortages drive scramble for metal.

The R2 SUV is expected to be launched in the first half of 2026.

The Pound Sterling consolidates around 1.3300 as investors await for Fed Kugler’s replacement and the BoE’s monetary policy outcome.

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its GAAP profit of $0.16 per share was in line with analysts’ consensus estimates.

Apple Inc. may be finding support here and doesn't seem to want to go down anymore, according to Ritholtz Wealth Management's Joshua Brown.